Kehan Xu1, Bo Li1, Quan Huang1, Dongjie Jiang1, Haitao Sun1, Nanzhe Zhong1, Wei Wan2, Haifeng Wei3, Jianru Xiao4. 1. Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu District, Shanghai, 200003, People's Republic of China. 2. Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu District, Shanghai, 200003, People's Republic of China. ggflyfish@126.com. 3. Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu District, Shanghai, 200003, People's Republic of China. weihfspine@163.com. 4. Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Huangpu District, Shanghai, 200003, People's Republic of China. jianruxiao83@smmu.edu.cn.
Abstract
BACKGROUND: To investigate the clinical significance of five inflammatory biomarkers and conventional clinical parameters in prognostic prediction of spinal chondrosarcoma. METHODS: Univariate and multivariate analyses were performed to investigate independent prognostic factors for recurrence and death of patients with spinal chondrosarcoma. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier curve, and differences were analyzed by log-rank test. The optimal cutoff values for NLR, PLR, LMR, and CAR were determined by X-tile program. RESULTS: The optimal cutoff value for NLR, PLR, LMR, AGR, and CAR was 2.7, 200, 3.0, 1.5, and 0.2, respectively. Of the 150 patients included, recurrence was detected in 105 patients, and death occurred in 78 patients. Multivariate analysis indicated that Tomita I-III, total resection, and CAR < 0.2 were significantly associated with longer DFS. Meanwhile, preoperative Frankel score D-E, total resection, and CAR < 0.2 were favorable prognostic factors for OS. Subtype analysis showed that only total resection was an independent prognostic factor for DFS of recurrent spinal chondrosarcoma. CONCLUSION: Total resection could significantly reduce the recurrence rate of spinal chondrosarcoma and improve OS of chondrosarcoma patients. Tomita classification I-III was a favorable factor for DFS, and preoperative Frankel score A-C was an adverse prognostic factor for OS. CAR was the most robust prognostic indicator with a discriminatory ability as compared with other inflammatory indicators. These slides can be retrieved under Electronic Supplementary Material.
BACKGROUND: To investigate the clinical significance of five inflammatory biomarkers and conventional clinical parameters in prognostic prediction of spinal chondrosarcoma. METHODS: Univariate and multivariate analyses were performed to investigate independent prognostic factors for recurrence and death of patients with spinal chondrosarcoma. Disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier curve, and differences were analyzed by log-rank test. The optimal cutoff values for NLR, PLR, LMR, and CAR were determined by X-tile program. RESULTS: The optimal cutoff value for NLR, PLR, LMR, AGR, and CAR was 2.7, 200, 3.0, 1.5, and 0.2, respectively. Of the 150 patients included, recurrence was detected in 105 patients, and death occurred in 78 patients. Multivariate analysis indicated that Tomita I-III, total resection, and CAR < 0.2 were significantly associated with longer DFS. Meanwhile, preoperative Frankel score D-E, total resection, and CAR < 0.2 were favorable prognostic factors for OS. Subtype analysis showed that only total resection was an independent prognostic factor for DFS of recurrent spinal chondrosarcoma. CONCLUSION: Total resection could significantly reduce the recurrence rate of spinal chondrosarcoma and improve OS of chondrosarcomapatients. Tomita classification I-III was a favorable factor for DFS, and preoperative Frankel score A-C was an adverse prognostic factor for OS. CAR was the most robust prognostic indicator with a discriminatory ability as compared with other inflammatory indicators. These slides can be retrieved under Electronic Supplementary Material.
Authors: P C W Hogendoorn; N Athanasou; S Bielack; E De Alava; A P Dei Tos; S Ferrari; H Gelderblom; R Grimer; K Sundby Hall; B Hassan; P C W Hogendoorn; H Jurgens; M Paulussen; L Rozeman; A H M Taminiau; J Whelan; D Vanel Journal: Ann Oncol Date: 2010-05 Impact factor: 32.976
Authors: H Ji; A M Houghton; T J Mariani; S Perera; C B Kim; R Padera; G Tonon; K McNamara; L A Marconcini; A Hezel; N El-Bardeesy; R T Bronson; D Sugarbaker; R S Maser; S D Shapiro; K-K Wong Journal: Oncogene Date: 2006-03-30 Impact factor: 9.867
Authors: S Boriani; F De Iure; S Bandiera; L Campanacci; R Biagini; M Di Fiore; L Bandello; P Picci; P Bacchini Journal: Spine (Phila Pa 1976) Date: 2000-04-01 Impact factor: 3.468
Authors: Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman Journal: Curr Treat Options Oncol Date: 2009-02-24
Authors: P Lissoni; F Brivio; L Fumagalli; G Messina; V Ghezzi; L Frontini; L Giani; M Vaghi; A Ardizzoia; G S Gardani Journal: Int J Biol Markers Date: 2004 Apr-Jun Impact factor: 2.659
Authors: Hans Gelderblom; Pancras C W Hogendoorn; Sander D Dijkstra; Carla S van Rijswijk; Augustinus D Krol; Antonie H M Taminiau; Judith V M G Bovée Journal: Oncologist Date: 2008-03
Authors: Angela Ylenia Giuffrida; Jorge E Burgueno; Leonidas G Koniaris; Juan C Gutierrez; Robert Duncan; Sean P Scully Journal: J Bone Joint Surg Am Date: 2009-05 Impact factor: 5.284